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Background: MBLs form a large and heterogeneous group of bacterial enzymes conferring resistance to b-lac-
tam antibiotics, including carbapenems. A large environmental reservoir of MBLs has been identified, which
can act as a source for transfer into human pathogens. Therefore, structural investigation of environmental and
clinically rare MBLs can give new insights into structure–activity relationships to explore the role of catalytic and
second shell residues, which are under selective pressure.
Objectives: To investigate the structure and activity of the environmental subclass B1 MBLs MYO-1, SHD-1 and ECV-1.
Methods: The respective genes of these MBLs were cloned into vectors and expressed in Escherichia coli. Purified
enzymes were characterized with respect to their catalytic efficiency (kcat/Km). The enzymatic activities and MICs
were determined for a panel of different b-lactams, including penicillins, cephalosporins and carbapenems.
Thermostability was measured and structures were solved using X-ray crystallography (MYO-1 and ECV-1) or
generated by homology modelling (SHD-1).
Results: Expression of the environmental MBLs in E. coli resulted in the characteristic MBL profile, not affecting
aztreonam susceptibility and decreasing susceptibility to carbapenems, cephalosporins and penicillins. The puri-
fied enzymes showed variable catalytic activity in the order of <5% to 70% compared with the clinically wide-
spread NDM-1. The thermostability of ECV-1 and SHD-1 was up to 8C higher than that of MYO-1 and NDM-1.
Using solved structures and molecular modelling, we identified differences in their second shell composition,
possibly responsible for their relatively low hydrolytic activity.
Conclusions: These results show the importance of environmental species acting as reservoirs for MBL-encoding
genes.
Introduction
The class B MBLs are enzymes with the ability to hydrolyse virtually
all b-lactam antibiotics, including carbapenems.1 Various MBLs,
including NDM, VIM and IMP, are associated with mobile genetic
elements and widespread among clinically important Gram-
negative pathogens. Phylogenetically, MBLs can be grouped into
three subclasses, B1 to B3.2 While enzymes belonging to sub-
classes B1 and B3 carry two Zn(II) binding sites (Zn1 and Zn2), B2
MBLs are mono-Zn(II) enzymes.2,3 In subclass B1, Zn1 is coordi-
nated by three histidine residues (His/Gly116, His118 and His196),
while the Zn2 binding site is coordinated by Asp120, Cys221 and
His263.2,4–7 In B2 MBLs, the Zn1 binding site displays one altered
residue (Asn116, His118 and His196), whereas the Zn2 site is iden-
tical to that of the subclass B1 MBLs.8,9 The subclass B3 MBLs ex-
hibit a variety of different Zn1 binding sites (His/Gln116, His118
and His196) and a distinct Zn2 binding site, which does not contain
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a cysteine residue (Asp120, His121 and His263). The Zn(II) ions are
bridged by a hydroxide ion most likely attacking the b-lactam
ring.4
Recently, 76 novel B1 MBL genes were predicted through large-
scale screening of genomic and metagenomics data.6 Some of
these enzymes exhibited sequence identities as low as 28% com-
pared with widespread MBLs like NDM-1.6 Carbapenemase activity
was experimentally confirmed for 18 of 21 tested MBLs when
expressed in Escherichia coli.6,10 This shows that there is a vast en-
vironmental reservoir of MBL genes that could potentially be
horizontally transferred into pathogenic bacteria and further com-
promise the effect of b-lactam antibiotics. Here, we investigated
three of these B1 MBLs,6 SHD-1, MYO-1 and ECV-1, in comparison
with the clinically widespread enzyme NDM-1. ECV-1 originated
from Echinicola vietnamensis, which has previously been isolated
from sea water.11 SHD-1 was identified in Shewanella denitrificans,
a genus that is known as the possible origin of resistance genes,
including genes encoding b-lactamases.12 MYO-1 was encoded on
a tet(X)-harbouring plasmid in Myroides odoratimimus, a widely
distributed bacterium in natural environments.13–16 The plasmid
also encoded a type IV secretion system, which could make it con-
jugatable.17 M. odoratimimus is not considered pathogenic under
normal circumstances;18 however, it has been reported to cause
opportunistic infections19–22 and treatment options are limited
since most strains display MDR.21,23–27
Methods
Strains and MIC determination
All strains used for MIC determination have been published previously.6 In
short, the candidate B1 MBL genes blaMYO-1, blaECV-1 and blaSHD-1 were syn-
thesized and sub-cloned into the pZE21-MSC1 vector (Expressys,
Ruelzheim, Germany). Recombinant plasmids were transformed into E. coli
C600Z1 (Expressys).6,28 For MIC determination, single colonies were incu-
bated overnight on Mueller–Hinton II agar (Becton Dickinson, Franklin
Lakes, USA) containing 25 mg/L kanamycin and subsequently suspended in
0.85% saline to a cell density with a turbidity equivalent to that of a
0.5 McFarland standard (1.5%107 cells/mL). The McFarland solution was
uniformly dispersed with a swab onto the agar plates containing 100 ng/
mL anhydrotetracycline (Sigma–Aldrich, St Louis, MO, USA). Gradient diffu-
sion strips (Liofilchem, Roseto degli Abruzzi, Italy) were applied and the
MICs were determined after 19 h of incubation at 37C.
Enzyme expression, purification and molecular mass
verification
For enzyme expression, we used synthetic and codon-optimized genes of
blaMYO-1, blaECV-1 and blaSHD-1 in a pDest17 vector (Thermo Fisher Scientific,
Waltham, USA) with a TEV cleavage site placed prior to the bla genes. The
genes were based on the bla genes found in M. odoratimimus,23 S. denitrifi-
cans and E. vietnamensis (GenBank accession numbers CP013691.1,
NC_007954.1 and NC_019904.1, respectively). The expression vectors were
electroporated into E. coli BL21-AI (Invitrogen, Carlsbad, USA). For protein
expression, cultures were induced with L-arabinose (0.1%; Sigma–Aldrich)
at an OD600 of 0.5. Expression was performed in Terrific Broth including
100 mg/L ampicillin (Sigma–Aldrich) at 15C and 225 rpm. TEV cleavage
and purification were done as previously described.29 Due to the TEV cleav-
age site and expression without the signal peptide, the protein sequences
start at position Gln30, Gly18, Val25 and Gly25 for MYO-1, ECV-1, SHD-1 and
NDM-1, respectively (additional glycine at the start). NDM-1 was expressed
and purified as described previously.30 For ESI-MS, the buffer was changed
to 0.1% formic acid (Merck Millipore, Burlington, USA) in centrifugal molecu-
lar cut-off filters (Merck MilliPore, 10000 Da) and concentrated to 0.25 g/L.
The protein masses were verified using an Orbitrap Fusion Lumos (Thermo
Fisher Scientific). Proteins were injected using an EASY-nano LC (Thermo
Fisher Scientific) with a 15 cm C18 EASY-Spray column. Masses were calcu-
lated using the BioPharma Finder 3.0 protein deconvolution software
(Thermo Fisher Scientific).
Zn66 determination
Inductive coupled plasma MS (ICP-MS) was used to determine the Zn(II)
concentration (Zn66) of purified protein in Zn(II)-depleted 50 mM HEPES
buffer (Chelex-HEPES buffer), pH 7.5. The Chelex buffer was prepared by stir-
ring 2 g of Chelex resin (Bio-Rad, Hercules, USA) in 100 mL of 50 mM HEPES
buffer, pH 7.5. The resin was subsequently removed by sterile filtration
(Merck MilliPore, 0.22lm). Purified proteins (10 g/L) were diluted to
100 mg/L in Chelex-HEPES buffer. Residual Zn(II) was removed from the
proteins by washing with Chelex-HEPES buffer in centrifugal molecular cut-
off filters (Merck MilliPore, 10000 Da). Samples were 1/16 diluted with
750 lL of a diluent mixture containing Rh103 (Inorganic Ventures,
Christiansburg, VA, USA) as internal standard. The diluent mixture consisted
of Milli-Q water (Millipore/Merck KGaA, Darmstadt, Germany) with 2 lg/L
Rh103, 2.5% (v/v) ammonia solution (Honeywell Fluka, Bucharest,
Romania), 0.08% (v/v) Triton X-100 (Sigma/Merck KGaA, Darmstadt,
Germany), 10% (v/v) isopropanol (Honeywell Fluka) and 0.25 lg/L Au
(Inorganic Ventures) as stabilizer. The samples were introduced to the
nebulizer (N2 gas flow 1.03 mL/min) by an ESI-Fast SC2DX autosampler
with a sample flow rate of 3 rpm and further into the NexION 300 D ICP-MS
system (Perkin Elmer, Waltham, MA, USA). For the MS analysis the kinetic
energy discrimination mode with a helium flow rate of 5.7 mL/min, 20
sweeps per reading and a dwell time of 100 ms/AMU for Zn(II) and 50 ms/
AMU for Rh103 were applied. The measurements were performed with the
following instrumental settings: rf power, 1600 W; plasma gas flow, 18 mL/
min Ar; auxillary gas flow, 1.2 mL/min N2; RPQ voltage, 0.25 V; and integra-
tion time, 2000 ms. All Zn(II) concentrations were obtained by the internal
standard method followed by a blank subtraction using the NexION soft-
ware version 1.5 (Perkin Elmer, Waltham, MA, USA). The Zn(II) concentra-
tion within the samples was determined based on an external calibration
curve.
Thermostability
Fluorescence-based thermal stability of the enzymes was determined.31 In
short, purified enzymes were diluted to 0.2 mg/mL using 50 mM HEPES buf-
fer pH 7.5 supplemented with 100lM ZnSO4 (Sigma–Aldrich) and 250 mM
NaCl (VWR, Radnor, USA). For the fluorescence signal, 12.5% SYPRO orange
(Sigma–Aldrich) was used. Melting curves were recorded across a tempera-
ture gradient (10–75C). Tests were performed in an MJ Minicycler (Bio-Rad,
Hercules, USA) and melting temperatures were calculated by using the Bio-
Rad CFX Manager (v. 3.1). All experiments were carried out in a final volume
of 25 lL and at least in triplicate. Purified NDM-1 was included as a control.
Steady-state enzyme kinetics
Km and kcat for recombinantly expressed enzymes were determined for
ampicillin (Dn =#820 M#1 cm#1, 235 nm, 1 nM), piperacillin (Dn =
#820 M#1 cm#1, 235 nm, 1 nM), nitrocefin (Dn = 17400 M#1 cm#1, 482 nm,
1 nM), ceftazidime (Dn =#9000 M#1 cm#1, 260 nm, 150 nM), cefepime
(Dn =#10000 M#1 cm#1, 260 nm, 1 nM), imipenem (Dn =#9000 M#1 cm#1,
300 nm, 1 nM) and meropenem (Dn =#6500 M#1 cm#1, 300 nm, 1 nM) by
measuring the initial enzymatic reaction rate at 25C. All determinations
were performed at least in duplicate at a final assay volume of 100lL. For
nitrocefin-dependent reactions, 96-well plates (Thermo Fisher Scientific,
Roskilde, Denmark) were utilized. For all the other drugs, UV-transparent
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performed in HEPES buffer 50 mM supplemented with 10 lM ZnSO4
(Sigma–Aldrich) and BSA (Sigma–Aldrich) at a final concentration of 2 lg/




Crystallization and structure determination
For ECV-1 (5 mg/mL), crystals were grown from reservoirs with 25%–26%
PEG3350 (Sigma–Aldrich), 0.1 M BIS-TRIS buffer pH 6 (Sigma–Aldrich) and
0.2 M sodium acetate (Sigma–Aldrich) at 4C. Crystal-containing drops
were diluted with 10 lL of reservoir solution and microcrystals were
created. Microcrystals were seeded into drops of 2 lL containing the
same composition and 5 mg/mL purified protein. For MYO-1 (5 mg/mL),
crystals were grown in 32%–36% PEG4000 (Sigma–Aldrich) and 0.2 M
ammonium sulphate at 4C (drop size 2 lL). Crystals were flash-frozen
in liquid nitrogen using 10% ethylene glycol (Sigma–Aldrich) in addition
to the reservoir solution. Since crystallization of SHD-1 was not success-
ful, we used SWISS-MODEL and the solved structure of TMB-1 (PDB ID:
5MMD) with sequence identity of 58%, to obtain a homology-modelled
structure.29,32
Diffraction data were collected at ID30A-3, at the European
Synchrotron Radiation Facility (ESRF), France, at 100 K, wavelength of
0.961 Å, and the diffraction images were indexed and integrated using
XDS.33 AIMLESS was used for scaling.34 For scaling, we aimed for high com-
pleteness, a CC1/2 >0.5 in the outer resolution shell and a mean <I> above
1.0 (Table 1). Both structures were solved by molecular replacement using
PDB ID: 1ZNB (ECV-1) and 1HLK (MYO-1) as search models and refined using
Phenix 1.12.35 Modelling was done using Coot.36 Figures were prepared
using PyMOL version 1.8 (Schrödinger).
Results
Environmental MBLs decrease susceptibility to
b-lactams in E. coli
The sequence identity of MYO-1, ECV-1 and SHD-1 was as low as
28% compared with the widespread MBL NDM-1 (Figure 1). We
identified differences in their loop regions L3 (residues 56–66),
L8 (residues 151–160) and L10 (residues 220–237), which are
involved in Zn(II) binding and defining substrate specificity.4 In
addition, MYO-1 and ECV-1 harboured in total three cysteine resi-
dues (positions 69, 121 and 221) within their active site. To explore
if the differences in the amino acid sequence could potentially in-
fluence the substrate specificity, we performed susceptibility test-
ing of E. coli expressing MYO-1, ECV-1 and SHD-1. The respective
genes (not codon-optimized) were sub-cloned into pZE21-MSC1
and expression was induced with anhydrotetracycline in E. coli
C600Z1 (Table 2). NDM-1 was included for comparison. All three
enzymes showed the characteristic MBL profile, increasing the MIC
of all b-lactams except for aztreonam. MBL activity was also con-
firmed by inhibition with EDTA. SHD-1 conferred the highest in-
crease in carbapenem MICs, with a 64-, 4- and 1024-fold increase
for ertapenem, imipenem and meropenem, respectively (com-
pared with E. coli C600Z1). The observed effect on carbapenem
MICs was lower for MYO-1 and ECV-1. Still, the expression of MYO-1
and ECV-1 resulted in an 8- and 16-fold increase in their ertapen-
em MICs and a 16- and 8-fold increase in their meropenem MICs,
respectively. In addition, MYO-1 led to a 4-fold increase in the imi-
penem MIC. Compared with NDM-1, which conferred MIC values of
cephalosporins of up to >256 mg/L, the MICs of cephalosporins
tended to be lower for all the environmental MBLs, ranging from
0.25 to >256 mg/L (4- to >512-fold change depending on the
cephalosporin). With the exception of piperacillin for MYO-1 and
ECV-1, the MICs of penicillins were increased by >4- to >32-fold.
For MYO-1 and ECV-1, an 8- and 4-fold increase in their MICs of
piperacillin was observed compared with a >256-fold increase for
NDM-1 and SHD-1, respectively.
Environmental b-lactamases possess lower activity than
NDM-1
Synthetic, codon-optimized genes were used to overexpress MYO-
1, ECV-1 and SHD-1 in E. coli. Protein purification yielded 50 mg
(MYO-1), 9 mg (ECV-1) and 62 mg (SHD-1) per litre of culture. The
purity of the enzymes was >95%. Computed monoisotopic mass
of tag-free MYO-1, ECV-1 and SHD-1 was confirmed by ESI-MS
to be 26771.6±3.3, 26348.2±0.3 and 25741.2±1.1 Da, respectively.
The Zn(II) content of MYO-1, ECV-1, SHD-1 and NDM-1 was
determined by ICP-MS and we found 2.0±0.1, 1.9±0.1, 1.7±0.1 and
1.7±0.1 Zn(II) atoms per enzyme, respectively. Thermostability
Table 1. X-ray data collection and refinement statisticsa
MYO-1 ECV-1
Data collection ESRF, ID30A-3 ESRF, ID30A-3
PDB entry 6T5L 6T5K
wavelength (Å) 0.961 0.961
space group P65 C2221
cell dimensions:









Rmerge 0.041 (0.790) 0.042 (0.591)
I/rI 11.2 (1.1) 8.1 (1.1)
completeness (%) 98.8 (99.6) 99.5 (95.4)
redundancy 3.5 (3.6) 5.6 (3.9)
CC1/2 0.998 (0.413) 0.999 (0.489)
Refinement
resolution (Å) 25.0–2.17 24.08–1.33
no. reflections 33586 49518
Rwork/Rfree 0.2172/0.2526 0.1550/0.1879











bond lengths (Å) 0.014 0.019
bond angles () 1.31 1.50
aValues in parentheses are for the highest-resolution shell.
bB factors of MYO-1 chain A.
cB factors of MYO-1 chain B.
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Figure 1. Multiple sequence alignment based on the MBL numbering system.72 For calculating the secondary structure elements, we used the pub-
lished structure of NDM-1 (PDB ID: 3ZR9).40 Sequence identity compared with NDM-1 was determined for MYO-1 (28%), ECV-1 (33%) and SHD-1
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measurements resulted in melting temperatures of 57.8±0.1,
60.8±0.3, 66.2±0.4 and 57.9±0.1C, respectively.
All enzymes showed catalytic activity against the tested b-lac-
tams (Table 3). In general, SHD-1 showed the lowest enzymatic
activity. Against penicillins and carbapenems, the catalytic activity
of SHD-1 was usually 2- to 4-fold lower compared with MYO-1 and
ECV-1. The activities of MYO-1 and ECV-1 were generally compar-
able to each other. The cefepimase and ceftazidimase activity of
MYO-1 was10-fold higher than that of SHD-1. The lower activity
of SHD-1 towards cephalosporins was due to both lower affinity
(Km >300 lM) and lower turnover (kcat 10 s#1). In line with the
MIC results, the b-lactamase activities of the environmental MBLs
were lower, ranging from <5% to 70%, compared with NDM-1
(Figure 2). For MYO-1, the catalytic activity tended to be higher and
its carbapenemase activity reached up to70% to that of NDM-1.
On the contrary, SHD-1 displayed the weakest comparative
carbapenemase and cephalosporinase activity, with values gener-
ally below 10%. In addition, ECV-1 demonstrated high catalytic ac-
tivity towards meropenem (65% compared with NDM-1), whereas
imipenem, penicillins and cephalosporins were hydrolysed to a
lower degree (10%–40%).
First shell, second shell and substrate binding residues
The structures of MYO-1 and ECV-1 were successfully solved by X-
ray crystallography to 2.17 and 1.33 Å, respectively (Figure 3a and
b and Table 1). For MYO-1 we found two molecules (chains A and
B) in the asymmetrical unit with Rwork and Rfree of 0.22 and 0.25
(space group P65). Due to lack of electron density in chain B, the
regions of N60 to K66, L93 to I96 and K104 to S105 could not be
built. The structure of ECV-1 was refined to an Rwork and Rfree of
0.16 and 0.19, respectively, with one molecule in the asymmetrical
Table 2. MICs (mg/L) for E. coli C600Z1 expressing blaMYO-1, blaECV-1 and blaSHD-1 sub-cloned into the pZE21-MSC1 expression vector; blaNDM-1 was
included as a comparator and empty vector was included as a control
E. coli C600Z1 E. coli C600Z1 pZE21-MSC1
E. coli C600Z1 pZE21-MSC1
blaMYO-1 blaECV-1 blaSHD-1 blaNDM-1
Penicillins
ampicillin 8 8 >256 >256 >256 >256
penicillin G 64 64 >256 >256 >256 >256
piperacillin 2 1 16 8 >256 >256
Cephalosporins
cefepime 0.064 0.064 8 0.25 2 >256
cefotaxime 0.5 1 16 8 >32 >32
cefoxitin 8 12 64 128 >256 >256
ceftazidime 0.5 0.25 >256 16 >256 >256
cefalotin 32 32 >256 >256 >256 >256
Carbapenems
ertapenem 0.032 0.032 0.25 0.5 2 16
imipenem 0.25 0.25 1 0.25 1 >32
meropenem 0.032 0.064 0.5 0.25 32 >32
meropenem/EDTA <0.032 <0.032 <0.032 <0.032 <0.032 <0.032
Monobactam
aztreonam 0.25 0.25 0.25 0.25 0.25 0.25
Table 3. Kinetic values (kcat, Km and kcat/Km) of recombinantly expressed and purified MYO-1, ECV-1, SHD-1 and NDM-1; errors are reported as stand-
ard errors
Substrate

























Ampicillin 130±9 1200±180 1.1%105 100±10 340±100 2.9%105 70±3 180±16 3.9%105 70±4 60±13 1.1%106
Piperacillin 70±3 140±20 5.0%105 300±20 550±90 5.5%105 70±10 180±52 3.9%105 180±17 140±55 1.3%106
Cefepime 30±3 180±40 1.7%105 5±1 70±11 7.1%104 8±2 550±160 1.5%104 12±4 30±4 4.0%105
Ceftazidime 50±4 130±30 3.9%105 30±3 340±57 8.8%104 10±1 340±72 2.9%104 12±1 20±4 6.0%105
Imipenem 40±1 50±6 8.0%105 20±1 60±6 3.3%105 40±2 210±20 1.9%105 8±1 75±4 1.1%106
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unit. For SHD-1, we used homology modelling since no crystal
structure was obtained. In addition, we found that the conserved
active site residues (first shell) coordinating Zn1 (H116, H118 and
H196) and Zn2 (D120, C221 and H263) were present in all three
enzymes (Figure 3c).
B1 MBLs usually share an H-bond network below the active site
involving second shell residues.37–39 These residues have been
shown to modulate substrate specificity and Zn(II) binding.39
Generally, the residues at positions 69, 70, 84, 115, 121 and 262
are part of this H-bond network (Figure 4). To investigate this H-
bond network, we superimposed the structures of MYO-1, ECV-1
and SHD-1 onto NDM-1 (PDB ID: 3ZR9).40 Superimposition resulted
in low root mean square deviation of 0.97, 1.03 and 0.92 Å, re-
spectively, and 0.72 Å for MYO-1 versus ECV-1. In contrast to the
complex H-bond network in NDM-1 involving Ser69, Asp84, Lys121
and Ser262, we found different amino acids in MYO-1 (Cys69,
Cys121, Gly262), ECV-1 (Cys69, Cys121, Gly262) and SHD-1 (Ala69,
Arg121, Gly262) (Figure 4). Asp84 was conserved in all four
enzymes. Compared with Arg121 (SHD-1) and Lys121 (NDM-1),
we found a third cysteine (Cys121) within the active site of MYO-1
and ECV-1. These cysteines (Cys69, Cys121, Cys221) were in the
vicinity of Asp120 (3–5 Å). The lack of Lys121 or Arg121 in MYO-1
and ECV-1 was compensated for by an extensive network of water
molecules (Figure 4). The L10 loop (residues 220–237) has been
described to be involved in Zn(II) binding and substrate specificity,
where the interaction with the substrate was due to hydrophobic
contacts.37 Interestingly, this loop was shortened by one residue
at position 231 in both MYO-1 and ECV-1. Moreover, we found vari-
ation in residues at positions 224 and 233, which have been
reported to play an important role in substrate recognition and hy-
drolysis in NDM and VIM variants.41,42 At position 233, asparagine
was present in both NDM-1 and ECV-1; however, we found tyrosine
in MYO-1 and SHD-1. In addition, we identified the amino acid sub-
stitution K224R in SHD-1 compared with NDM-1, ECV-1 and MYO-1.
Discussion
Here, we present two new crystal structures and one homology
model of MBLs identified in environmental bacteria.6 Expressed in
E. coli, all three enzymes conferred decreased susceptibility to car-
bapenems, cephalosporins and penicillins. Compared with NDM-1,
the expression of MYO-1, ECV-1 and SHD-1 led to lower MICs,
especially those of carbapenems (Table 2). We determined the
catalytic efficiency using purified enzymes. Generally, the enzym-
atic activity ranked MYO-1 > ECV-1 > SHD-1. We found the largest
differences in catalytic efficiency towards cephalosporins, where
MYO-1 exhibited up to 44-fold higher activity against cefepime
compared with SHD-1. Interestingly, SHD-1 conferred the highest
MIC values when expressed in E. coli, but the lowest catalytic
efficiencies (purified enzyme). SHD-1 was identified in a
Gammaproteobacterium, while the natural hosts of MYO-1 and
ECV-1 belong to the distant phylum of Bacteroidetes6 and hence
may not be expressed efficiently in the periplasm of E. coli. Work
on the subclass B1 SPM-1 has shown different drug selectivity when
tested in the periplasm, in enzyme kinetic assays and in an MIC set-
up.39 In addition, the expression of the same class B and D b-lacta-
mases in different hosts exhibited a lack of correlation between
MICs and the catalytic efficiency of these enzymes.43,44 Hence,
phenotypic variation can be due to differences in catalytic efficiency
in the periplasmic conditions, but expression level, protein folding
and translocation to the periplasm can also play a role.43
ECV-1 and SHD-1 exhibited thermostabilities 3 and 8C
higher than MYO-1 and NDM-1. Studies have shown that lower
thermostability was accompanied by higher flexibility, facilitating
cephalosporin hydrolysis in b-lactamases.45,46 Interestingly, the
more thermostable SHD-1 and ECV-1 showed lower catalytic effi-
ciency, especially against oxyimino cephalosporins. However, due
to the low sequence identity (28%) further studies have to be
conducted exploring the structure–activity relationships and a pos-
sible correlation with thermostability.
Since second shell residues have been reported to be under evo-
lutionary pressure and their substitutions have created variants
with changed enzymatic activity,38,47,48 we investigated the
structures of MYO-1, ECV-1 and SHD-1. We found the positions 69,
121 and 262 differed from the second shell residues of NDM-1. In
NDM-1, mutational studies of Ser69 and Lys121 revealed that a
cysteine replacement, as present in MYO-1 and ECV-1, reduced
bacterial fitness towards cefotaxime and imipenem, while Ala69
and Arg121 (SHD-1) improved bacterial survival after selection.49
The amino acid position 121 is semi-conserved as it is directly situ-
ated ‘below’ the Zn2 binding site. While crystallographic occupancy
correlated with reduced Zn(II) affinity for MBLs carrying Arg121
(e.g. BcII, VIM-2 and BlaB),50,51 high occupancy was seen for MBLs
carrying serine or cysteine at this position, e.g. IMP-1 and CcrA.52–54
Mutational studies of BcII:R121C showed a marginal increase in oc-
cupancy compared with WT BcII.55 In contrast, C121R in CcrA
resulted in a variant with lower Zn(II) affinity.56 Arg121 interacts
with Asp120 in BcII and data suggest that R121C may affect the
pKa of Asp120, thus changing the pH-dependent activity of the en-
zyme.57 Interestingly, in BcII:R121C a network of water molecules
populates the active site as a replacement for a guanidinium group
of arginine that usually preserves its shape.55 G262S differentiates
IMP-1 from IMP-6 and has been shown to also enhance catalytic
efficiency in both IMP and BcII.58 Precursor enzymes of IMP-1 have
therefore been reported to be less active against, for example,
ampicillin, ceftazidime and imipenem.59,60 In addition, an amino
acid substitution of G262S in IMP-1 suggested reduced mobility of
His263 by the formation of an H-bond network allowing the ac-
commodation of cephalosporins.61–63 We confirmed the presence
of an extensive water-mediated H-bond network within the active
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Figure 2. Relative catalytic efficiencies [kcat/Km (s
#1 M#1)] of MYO-1,
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Cys121 and Gly262 (Figure 4). Tyr244 in NDM-1 has been shown to
stabilize the L10 loop by the formation of hydrophobic interactions
with, for example, Leu222, Leu231 and Leu234.64–69 We found
Leu231 to be deleted in MYO-1 and ECV-1 as well as a substitution
at position 234 to threonine in SHD-1. Mutational studies of NDM-1
with L231F resulted in a decreased hydrolytic activity towards
Figure 3. Overall fold of (a) MYO-1 (chain A) and (b) ECV-1 with the crystallographically assigned B values (left), where blue represents low B factors
and red represents high B factors (colour code scaling of B factors from 20 to 75 Å2), and their active site amino acids including the corresponding
2Fo-Fc map (right). Temperature factors for MYO-1 were generally higher than for ECV-1. However, both structures showed high variation in their
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carbapenems, penicillins and cephalosporins.70 The amino acids
located at 224 and 233 have been reported to be important in sub-
strate recognition and hydrolysis.41,42
In conclusion, this work presents the structure and activity of
three MBLs from environmental sources. We showed that these
enzymes act as carbapenemases exhibiting increased catalytic ac-
tivity and conferring elevated MICs when expressed in E. coli. The
lower activity towards cephalosporins and carbapenems could be,
at least partially, explained by their second shell residues. These
residues have been previously shown to be under selective pres-
sure in other enzymes, and amino acid substituents may alter
Zn(II) binding and extend their substrate specificity.38,47,48,56–60
Mobilization and horizontal transfer of genes expressing these or
similar enzymes into clinical strains may render those strains less
susceptible towards carbapenems and carbapenemase inhibitors
acting as Zn(II) chelators.71
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